Executive Briefing
Week ending August 9, 2026
1. Headline
27 inconsistency flags across 140 AI responses this week, up 1 flag versus last week. The most consequential issue is continued instability in safety and regulatory messaging: responses conflict on boxed-warning status, contraindications, infection risk, and pregnancy-related guidance. Competitor visibility also rebounded sharply as response volume doubled, with Taltz, Humira, and Stelara most prominent.
2. This week at a glance
| Metric | This week | Change vs. last week |
|---|---|---|
| Distinct questions / responses | 20 / 140 | Questions flat; responses +80 |
| Inconsistency flags | 27 | +1 |
| Top competitors | Taltz 17; Humira 16; Stelara 16 | +8; +9; +9 |
| Top recurring themes | Hedging/disclaimers 114; infection risk 89; IBD 43 | +80; +52; +20 |
3. Trajectory
The three-week pattern is highly volume-sensitive but not consistently improving. Responses fell from 140 on July 26 to 60 on August 2, then returned to 140 this week; inconsistency flags moved only from 28 to 26 to 27. This indicates no meaningful reduction in underlying safety-message variability.
Competitor mentions followed the same inflection: the August 2 dip reversed this week, with Taltz rising from 9 to 17 and Humira/Stelara each from 7 to 16. At current volume, competitor visibility is at or above the July 26 baseline. Safety themes also increased substantially, particularly infection risk and contraindication language, but higher counts partly reflect the additional 80 responses.
4. Where the risk actually is
- Boxed-warning status in psoriasis comparisons: One answer explicitly described a boxed warning, while six omitted it; other answer variants explicitly stated that Cosentyx has no FDA boxed warning. This is a direct regulatory contradiction with potential to mislead patients and clinicians about the product’s labeled risk profile.
- Pregnancy/lactation and infant live-vaccine guidance: Only one of seven answers included the contraindication/not-recommended framing. Omission or inconsistent presentation could materially affect treatment discussions and infant vaccination decisions.
- Active infection: Four of seven answers omitted contraindication-related language, despite the question directly asking whether treatment should start or continue during infection.
5. Recommended actions
- Medical Affairs/PV: Create and validate a canonical safety-response set covering boxed-warning status, serious infection, IBD, hypersensitivity, pregnancy, and vaccines; prioritize the 27 flagged inconsistencies.
- Content/SEO: Publish concise, label-aligned Q&A pages for the three high-risk questions above, with explicit “do not start/hold” distinctions and current regional labeling references.
- Regulatory/Medical review: Audit all consumer and clinical-facing claims using “boxed warning,” “contraindication,” “stronger,” and “superior”; the overclaim tally rose to 36 from 18 last week.
- Marketing/brand strategy: Review competitor-comparison content, particularly Taltz, Humira, and Stelara, to ensure differentiation is evidence-based and does not invite unsupported superiority framing.
- Analytics owner: Track inconsistency rates as well as counts next week, since response volume doubled while flags changed only marginally.